Adopting AI in biologics discovery 

In partnership with:

Read our report and…

• Learn about the benefits of adopting AI in biologics discovery 
• Understand the significance of the biologics market and how AI can drive its growth 
• Take a look at practical challenges biologics developers face when adopting AI and the triad of robust data infrastructure, advanced computational capabilities, and multidisciplinary human capital needed for successful AI adoption in biologics discovery  
• Gain exclusive insights from executives at Boehringer Ingelheim, Daiichi Sankyo Europe, OncoHost, and others.

More about this report:

The global market share of biologics was estimated at $400 billion in 2024 and is expected to reach over $650 billion by 2030. At this rate, the global market size of biologics could even outpace that of small molecules in the coming years. 

Given the complex biology of these candidates, AI is becoming a valued tool for saving time and cutting cost in biologics discovery.  

Our comprehensive report, produced in partnership with ENPICOM, delves into current trends and developments concerning AI in biologics discovery, and highlights worthwhile considerations for life science companies to take into account in their AI adoption strategies.